Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin businesses feel the strain despite a strong dollar.

Veru Inc (NASDAQ:VERU) reported positive top-line results from its Phase 2B clinical study for Novosarm, showing significant preservation of lean body mass in older patients. The company ...

Veru (NASDAQ:VERU) Inc. reported its Q1 FY2025 earnings, revealing a net loss per share of $0.06, which was better than the projected loss of $0.08. The company's revenue reached $3.2 million ...

$VERU insiders have traded $VERU stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales. Here’s a ...

VERU has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Veru in a research note on Thursday, January 2nd ...

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation, pharmacokinetic ...

Veru Inc (NASDAQ:VERU) reported positive top-line results from its Phase 2B clinical study for Novosarm, showing significant preservation of lean body mass in older patients. The company successfully ...

Veru Inc. (NASDAQ:VERU – Get Free Report) was the recipient of a large increase in short interest in the month of January.As of January 31st, there was short interest totalling 14,620,000 shares ...

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation ...